Page last updated: 2024-12-04

5-hydroxydecanoate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-hydroxydecanoic acid: Potassium Channel Blocker; RN refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1825
CHEMBL ID1373782
CHEBI ID165412
SCHEMBL ID316603
MeSH IDM0149901

Synonyms (38)

Synonym
5-hydroxydecanoate
decanoic acid, 5-hydroxy-
5-hydroxydecanoic acid
BIO2_000764
BIO1_000844
BIO1_000355
BIO1_001333
BIO2_000284
BSPBIO_001564
LOPAC0_000628
624-00-0
5-hydroxy capric acid
LMFA01050032
5-hydroxy-decanoic acid
NCGC00163138-02
NCGC00163138-01
KBIO2_005420
KBIOGR_000284
KBIO3_000568
KBIOSS_000284
KBIO2_000284
KBIO3_000567
KBIO2_002852
IDI1_034034
NCGC00163138-03
HMS1989O06
5-hydroxycapric acid
CHEBI:165412
HMS1791O06
AKOS006294395
SCHEMBL316603
LMHJFKYQYDSOQO-UHFFFAOYSA-N
CHEMBL1373782
HMS3402O06
xi-5-hydroxydecanoic acid
SDCCGSBI-0050609.P002
m-14157
DTXSID10977956

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In a first study to characterize effects of sex and the dose-response profile of estrogen on infarct size, the drug was intravenously administered at 10 or 20 microg/kg."( Cardioprotective effects of 17 beta-estradiol produced by activation ofmitochondrial ATP-sensitive K(+)Channels in canine hearts.
Lee, TM; Lee, YT; Su, SF; Tsai, CC; Tsai, CH, 2000
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
medium-chain fatty acidAny fatty acid with a chain length of between C6 and C12.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
regulator of G-protein signaling 4Homo sapiens (human)Potency18.88760.531815.435837.6858AID504845
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (425)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (0.47)18.7374
1990's49 (11.53)18.2507
2000's260 (61.18)29.6817
2010's107 (25.18)24.3611
2020's7 (1.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.83 (24.57)
Research Supply Index6.07 (2.92)
Research Growth Index6.53 (4.65)
Search Engine Demand Index17.79 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (0.46%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other429 (99.54%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]